We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Immune Biomarker May Help Detect Ovarian Cancer Two to Four Years Earlier

Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Researchers at Children’s Hospital of Philadelphia (CHOP) announced the discovery of a novel immune-based biomarker that could pave the way for potential lifesaving early detection of high-grade ovarian cancer (HGOC). The findings were published today in the journal Cell Reports Medicine.

High-grade ovarian cancer (HGOC) is the fifth-leading cause of cancer-related death among women.  More than 90% of women are diagnosed when the disease has reached advanced stages and has already spread, presenting significant treatment challenges. Ovarian cancer is highly treatable when caught early, but tests that look for conventional biomarkers haven’t been able to detect microscopic, metastatic early lesions that often develop in the fallopian tubes. However, with the discovery of a novel immune-based biomarker, there is potential to change the trajectory for many women.

Although CHOP is a pediatric environment, its comprehensive Research Institute is dedicated to improving children’s lives and helping them thrive into adulthood through transformative solutions, such as new diagnostic tools, medicines, technologies, and policy recommendations. By tackling the most pressing healthcare challenges, CHOP dramatically advances wellness beyond pediatrics across the entire lifespan.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

In this study, researchers at CHOP and UT Southwestern Medical Center in Dallas analyzed T-cell receptors (TCRs) in nearly 500 blood samples from pre-diagnostic patients with ovarian cancer, as well as healthy/benign controls from the Nurses’ Health Study. TCRs are proteins found on T cells, a type of immune cell that recognizes and binds to foreign substances.

Study analysis revealed that in the early stages of HGOC, approximately two to four years before most cases of HGOC are currently diagnosed, a healthier immune system reacts significantly stronger, producing a measurable biomarker. Therefore, researchers deduced that tracking the disease within that specific timeframe, before a shift in the body’s immune response, allowed for earlier treatment interventions.

The researchers also noted that additional research is needed to aid in the development of a diagnostic test sensitive enough to detect the novel immune biomarker. They envision the testing as a compliment to current approved HGOC screening protocols.

Reference: Yu X, Pan M, Ye J, et al. Quantifiable TCR repertoire changes in prediagnostic blood specimens among patients with high-grade ovarian cancer. Cell Rep Med. 2024:101612. doi: 10.1016/j.xcrm.2024.101612

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.